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What is the central question of this study? 
Are the urinary levels of NO and ATP, and their metabolites, associated with the symptom 
severity of overactive bladder? 
What is the main finding and its importance? 
The urinary ratios of [ATP/NO], [ADP/NO] and a combination of these, 
[ATP/Cr*ADP/Cr]/[NO/Cr] were correlated with overall OAB symptom severity; with the 
latter also correlating with the severity of urinary frequency and urgency symptoms 
individually. Together these data reveal changes in urothelial signalling that accompany the 
transition from physiology to pathology. 





Overactive bladder (OAB) is a highly prevalent symptom complex characterized by 
symptoms of urinary urgency; increased frequency; waking to void (nocturia) - with or 
without urge incontinence and in the absence of proven infection or other obvious 
pathology. The underlying pathophysiology of idiopathic OAB is not clearly known and the 
existence of several phenotypes has been proposed. Current diagnostic approaches are 
based on discordant measures, suffer from subjectivity and are incapable of detecting the 
proposed OAB phenotypes. NO, ATP and their metabolites have previously been shown to 
underlie the perception of bladder fullness, with their release modifying the pathological 
perception of urgency. Therefore, in this study we assessed the concentration of NO, ATP 
and associated metabolites in the urine of 113 consented participants recruited from the 
general population.  
Recruited participants completed a questionnaire to measure the severity of OAB-
associated urinary symptoms and provided a mid-stream urine sample. Following 
identification of infection and hematuria using microbiology and microscopy, 95 samples 
were subjected to assays to measure NO, NO2
-, NO3
-, ATP, ADP and creatinine. 
There was no correlation between [NO/Cr], [NO2
-/Cr] or [NO3
-/Cr] and overall OAB symptom 
severity. [ATP/NO], [ADP/NO] and a combination of these, [ATP/Cr*ADP/Cr]/[NO/Cr], 
correlated with OAB symptom severity; with [ATP/Cr*ADP/Cr]/[NO/Cr] also correlating with 
the severity of urinary frequency and urgency. 
This study adds to a growing literature that demonstrates the potential of urinary 






Overactive bladder (OAB) is defined by the presence of bothersome symptoms of urinary 
urgency, increased frequency, nocturia, with or without urge incontinence in the absence of 
proven infection or other obvious pathology (Drake, 2014).  
The initial evaluation of idiopathic OAB includes the assessment of the severity of OAB 
characteristic symptoms and the exclusion of disorders that present with some overlapping 
symptoms. However, there is no consensus regarding the symptom severity and/or 
symptom combination for OAB diagnosis or to define treatment response. This is considered 
as a challenge for interpretation, replication or clinical implementation of observed findings 
from studies to date (Lightner et al., 2019). In addition, the identification of subgroups of 
patients presenting with distinct combinations of OAB characteristic symptoms and/or 
bothersome severities, suggest the existence of several OAB phenotypes. This hypothesis is 
further supported through the observation of discrepancies in the clinical validity and 
benefits of several OAB diagnostic approaches that have been thus far utilized. For instance, 
the presence of urodynamically-demonstrable detrusor overactivity (DO) was only observed 
in half of the patients presenting with OAB characteristic symptoms, while DO was present 
in two-thirds of those without any OAB symptoms (Rovner and Goudelocke, 2010). OAB is a 
symptom complex and exists in several phenotypes. Considering this, the conventional 
approach of dichotomous participant stratification utilized in preliminary biomarker 
discovery studies needs to be replaced. The most suitable alternative would be to identify 
biomarkers that are specific to OAB phenotypes based on individual OAB characteristic 




Urinary biomarkers are proposed to be valuable tools in identifying OAB phenotypes and for 
the selection of more effective targeted therapies (Antunes-Lopes and Cruz, 2019). A 
growing number of studies have shown the ability of the urothelium to release various 
chemical factors including nitric oxide (NO) and ATP (Birder and de Groat, 2007), where the 
release is considered as being in a bidirectional manner into the bladder’s mucosal layer and 
lumen (urine) (Yoshida et al., 2006). It was suggested that changes in their released levels 
may modulate bladder sensory signaling pathways and if their altered urinary levels 
correspond to the severities of OAB symptoms, then they may be used as non-invasive OAB 
biomarkers. In a study by Munoz and colleagues (2011), the urinary ratio of ATP/NO was 
significantly higher in overactive bladders from diabetic rats compared to underactive or 
control bladders (Munoz et al., 2011). Therefore it was proposed that the urinary ATP/NO 
ratio may be a sensitive clinical biomarker to characterize the extent of bladder dysfunction. 
These observations prompted us to undertake a pilot study to investigate the associations of 
urinary concentrations of urinary NO, ATP and their metabolic derivatives with OAB bladder 
symptom severity in 113 participants. We aimed to identify whether these urinary 
surrogates could be used as markers of OAB severity and potentially as means for 






Materials and Methods 
Ethical Approval 
All participants recruited to this study provided informed consent in writing. The work was 
approved by the NHS Research Ethics Committee South Central, reference 13/SC/0501 and 
the Ethics Committee of the School of Pharmacy and Biomedical Sciences at the University 
of Portsmouth. The study conformed to the standards set by the Declaration of Helsinki, 




Participant recruitment and methods performed on data and samples are together 
summarized in Figure A1. One hundred and thirteen volunteer participants were recruited 
(2014-2016) according to the inclusion and exclusion criteria (see below) to this study. 
Consented participants were asked to complete the ICIQ-OAB questionnaire and to provide 
a fresh urine sample. Urine samples were immediately placed on ice for transport to the 
University of Portsmouth, where they were processed as described below.  
Inclusion Criteria: Male or female participants aged ≥18 years and able to give informed 
consent for participation in the study.  
Exclusion Criteria: Male or female participants aged ≤18; taking any medication for OAB; 
unable to give informed consent; diagnosed with a neurologic disease (stroke, MS, 
Parkinson’s disease, spinal cord injury); with a history of uterine, cervical, vaginal or urethral 
cancer; history of cyclophosphamide use or any type of chemical cystitis; history of benign 
or malignant bladder tumors; have had Botulinum toxin injections into the bladder, 





Urine pathology tests 
Microscopic examination, dipstick urinalysis and chromogenic urinary tract infection (UTI) 
medium tests were immediately performed on a small proportion of each collected urine 
sample. According to the performed tests, 10 participants were diagnosed as having a 
yeast/bacterial infection or hematuria and four did not meet the inclusion criteria and 
therefore these participants were excluded from the study. The remaining urine samples 
(n=95) were utilized for biomarker analyses.  
Following urine pathology tests, the remainder of the urine sample was centrifuged (at 4000 
rpm, 10 mins, at 4°C), separated into cell pellet and supernatant and stored at -80°C before 
being subjected to biomarker analyses. 
Biomarker assays 
Creatinine (Cr) Assay 
The concentration of urinary (cell-free component) Cr was measured using the Cayman 
Creatinine (urinary) Colorimetric Assay Kit (CAY500701, Cambridge Bioscience, UK), 
following the manufacturer’s instructions. All urinary biomarker values were normalized to 
corresponding Cr concentrations. 
ATP Assay 
The concentration of urinary (cell-free component) ATP was measured using ENLITEN® ATP 
Assay System Bioluminescence Detection Kit (FF2000, Promega, UK) according to the 
manufacturer’s instructions. Briefly, 40µL of each standard and urine samples, in duplicates, 




luminescence was measured (POLARstar Optima microplate reader, BMG LABTECH, UK) 
before and after the addition of luciferin-luciferase (40µL) mixture. Calculated ATP 
concentrations were normalized to their corresponding urinary creatinine values (ATP/Cr).  
Nitric Oxide (NO) measurement 
NO has a short half-life and is converted rapidly to its oxidation products Nitrite (NO2
-) and 
Nitrate (NO3
-). The urinary (cell-free component) concentrations of NO2
- and NO3
- were 
measured using Nitric Oxide Analyzer (Sievers (NOA™ 280i), Analytix, UK). To measure [NO2
-
], the reducing agent iodide in glacial acetic acid was used to convert NO2
- to NO (at ambient 
temperature). Under these conditions only NO2
- and S-Nitrosothiol (if present) would be 
reduced to NO for measurement. To measure NO3
-, Vanadium (III) Chloride in 1N 
hydrochloric acid was used to convert NO3- to NO (at 95
oC). Under these conditions not only 
would the NO2
- and S-Nitrosothiol be reduced to NO but also the Nitrate. Therefore, the 
total [NO] is the same as the [NO3
-] in this experimental situation. Hence, [NO3
-] was 
calculated by deducting the [NO2
-] value from the total [NO] value. The NO, NO2
- and NO3
- 






For each of the analyses made, the characteristics of participants (including age, gender and 
urinary symptom score profiles) are summarised in Table A1. D'Agostino-Pearson normality 
test (where appropriate) was performed on all the generated data. Pearson product-
moment correlation coefficient (parametric) or Spearman's rank correlation coefficient 




Prism 8.0.0 software was used for all the analyses and the preparation of lin-log correlation 






The urinary concentrations of NO, NO2
-, NO3
-, ATP and ADP were measured in 95 human 
urine samples. Concentrations were standardized to their corresponding urinary creatinine 
concentrations and their relationships with participants’ OAB-associated urinary symptoms 
and age were investigated (Table 1). 
There was no correlation between [NO/Cr], [NO2
-/Cr] or [NO3
-/Cr] and overall OAB symptom 
severity (i.e. total ICIQ-score) (Table 1; Figure 1Aa). There was a positive correlation 
between [NO2
-/Cr] and the severity of urinary frequency (Table 1) but there were no other 
associations between [NO/Cr], [NO2
-/Cr] or [NO3
-/Cr] and the severity of individual urinary 
symptoms that define OAB (Table 1). 
In order to address the hypothesis that NO in combination with ATP (i.e. the ATP/NO ratio) 
may be a sensitive clinical biomarker to characterize the extent of bladder dysfunction 
(Munoz et al. 2011), this ratio was correlated with OAB symptom severity. There was a 
positive correlation between [ATP/NO] and total ICIQ-score, urinary frequency but also age 
(Table 1; Figure 1Aa). Given that the concentration of the hydrolysis product of ATP, ADP, 
correlated with total ICIQ-score and a positive correlation between [ATP/Cr] and [ADP/Cr] 
(Figure 1Ba) was observed, the combined concentrations of ATP, ADP and NO (i.e. 
[ATP/Cr*ADP/Cr]/[NO/Cr]) were correlated with OAB symptom severity and a positive 
relationship was observed (Figure 1Bb). [ATP/Cr*ADP/Cr]/[NO/Cr] was also positively 
correlated with urinary frequency and urgency but not nocturia or incontinence severity 
(Table 1). 
The influence of gender on the relationships between urinary concentrations of chemicals 




biomarkers / biomarker combinations overlap. The small sample sizes of gender groups 








Overactive bladder (OAB) is a symptom complex with a profound impact on many aspects of 
sufferers’ quality of life (Milsom et al., 2012). Our understanding of the pathophysiological 
mechanisms underlying its development is limited but an association with multiple factors 
has led to the notion of the existence of several OAB phenotypes (Peyronnet et al., 2019); 
potentially identified by specific urinary biomarkers (Antunes-Lopes and Cruz, 2019). 
Therefore, in this study we aimed to investigate the validity of urinary biomarkers in human 
participants with mild to moderate OAB symptoms, in order to address the utility of these 
urinary biomarkers in early detection. 
As urgency is the key OAB symptom (Abrams et al., 2012), we focused on chemicals thought 
to initiate it: ATP and NO, released from the urothelium, and shown to mediate the afferent 
signaling system (Birder and Andersson, 2013); in turn responsible for the perception of 
bladder fullness in health and its upregulated state of urgency in disease. 
It was hypothesized that urinary [NO] would negatively correlate with OAB symptom 
severity, given evidence from animal studies that (i) NO increased the interval between 
bladder contractions without changes in contraction amplitude (Ozawa et al., 1999), (ii) a 
NO scavenger stimulated overactivity (Pandita et al., 2000), and (iii) mucosa-derived NO 
release was reduced in disease models (Munoz et al. 2011). In our study, urinary [NO/Cr], 
[NO2
-/Cr] or [NO3
-/Cr] did not correlate with overall OAB symptom severity (Table 1). This 
disparity is likely due to differences in experimental design; as previous studies used animal 
models of disease rather than humans or biomarkers of human bladder function. 
We did, however, observe an altered [ATP/NO] with bladder dysfunction, as has been 




positive correlation between [ATP/NO] and both total ICIQ symptom score and the severity 
of urinary frequency. Utility of this combination is improved when the urinary concentration 
of ADP, the product of ATP hydrolysis, is included: there were positive correlations between 
[ATP/Cr*ADP/Cr]/[NO/Cr]) and OAB symptom severity, urinary frequency and urgency. To 
our knowledge, this is the first study in humans to demonstrate the utility of these 
biomarker concentrations. We hypothesize that OAB is characterized by an increase in 
urothelial ATP release - as observed by increased urinary [ATP] in OAB (Silva-Ramos et al., 
2013); interstitial cystitis (Sun et al., 2001); and benign prostatic hypertrophy (Silva-Ramos 
et al., 2016) - and a small decrease in urothelial NO release. Measuring a combination of 
urinary biomarkers provides a more sensitive measure of small changes in bladder function 
attributable to disease onset. 
It should be noted that by recruiting participants from the general population, we observed 
a range of symptom scores with the majority of participants exhibiting mild symptoms. In 
some ways this is advantageous, as biomarkers/biomarker combinations specific to 
pathogenesis or early onset offer the most utility to the scientific and clinical community. 
Future studies should, however, recruit participants across the entire range of the OAB 
symptom spectrum. 
The relationships between urinary concentrations of putative biomarkers and OAB symptom 
severity appear similar between the gender groups (Figure A2). Small sample sizes of gender 
groups limit the conclusions that can be drawn from these data. Future studies should 
therefore aim to recruit an equal number of participants from both genders in order to 




By ruling out similarly presenting conditions at the point of recruitment (see ‘Exclusion 
criteria’) and by performing urine pathology testing, we had hoped to recruit participants 
with a spectrum of lower urinary tract symptoms attributable to OAB. We acknowledge, 
however, that the ICIQ-OAB questionnaire lacks the ability to differentiate between 
different types of incontinence such as urge urinary incontinence, mixed urinary 
incontinence or stress incontinence. Although all the participants in this study with 
incontinence (i.e. an incontinence score of >0) had other OAB characteristic symptoms, 
more needs to be done in the future to differentiate between different types of 
incontinence. Furthermore, we cannot rule out the possibility that OAB was secondary to 
outflow obstruction. Future studies should therefore either involve participants with a 
broad range of OAB symptoms in order to allow the identification of further OAB 
phenotypes, and should be extended to include more participants and those with mixed 
urinary incontinence or, alternatively, include more rigorous recruitment criteria to exclude 
other possible overlapping conditions such as stress incontinence and polyuria. 
Furthermore, the clinical utility of biomarker combinations should be tested in large, 
longitudinal studies. 
Conclusions 
Given a paucity of knowledge of OAB pathogenesis, there is a need to develop tools (i) to 
allow early detection, (ii) to differentiate from other, similarly presenting symptom 
complexes/diseases, and (iii) as an objective means to monitor the effects of treatment. In 
this pilot study (n=113) sampling from the general population, we demonstrate positive 
correlations of [ATP/Cr], [ADP/Cr], [(ATP/NO)/Cr] and [ATP/Cr*ADP/Cr]/[NO/Cr]) with OAB 




and urgency. This study adds to a growing literature that demonstrates the potential of 






Table 1. Correlations between the urinary nitric oxide (NO), nitrite (NO2
-), nitrate (NO3
-) and 
the ratio of urinary ATP and/or ADP to NO with overactive bladder characteristic symptoms 
severity and age. 





















p 0.290 0.000 0.095 0.001 0.402 0.003 




p 0.598 0.288 0.477 0.898 0.469 0.877 




p 0.785 0.502 0.878 0.134 0.131 0.015 





p 0.711 0.708 0.521 0.189 0.207 0.293 





p 0.637 0.303 0.760 0.007 0.021 0.015 







p 0.882 0.772 0.889 0.022 0.038 0.032 
r -0.018 0.035 -0.017 0.309 0.294 0.363 
Age p 0.660 0.312 0.952 0.022 0.696 0.249 
r 0.048 -0.112 0.007 0.281 0.051 0.178 
Urinary concentrations of NO, NO2
-, NO3
-, ATP and ADP were normalised to urinary 















Figure Legends  
Figure 1. Associations of nitric oxide (NO), nitrite (NO2
-), nitrate (NO3
-) and the ratio of 
urinary ATP and/or ADP to NO with overactive bladder (A) a. Correlation between the 
urinary levels of NO and participants’ total ICIQ-OAB severity scores; b. Correlation between 
the ratio of urinary ATP to NO and participants’ total ICIQ-OAB severity scores; c. Correlation 
between the ratio of urinary ADP to NO and participants’ total ICIQ-OAB severity scores. (B) 
a. Correlation between participants’ urinary ATP and ADP; b. Correlation between the ratio 
of the combination of urinary ATP and ADP to NO and participants’ total ICIQ-OAB severity 
scores. 
Urinary concentrations of NO, ATP and ADP were normalized to urinary creatinine (Cr) 
concentration. p: p-value. r: Spearman/Pearson r value. P<0.05 are in bold. All data 
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Figure A1. Flow diagram of participants’ recruitment, selection and subsequent tests.  
a: See Methods and Materials section for inclusion and exclusion criteria; ICIQ-OAB: 
International consultation on incontinence questionnaire - overactive bladder; UTI: Urinary 
tract infection; NO: Nitric oxide; NO2
-: Nitrite; NO3
-: Nitrate. b: Urinary concentrations of NO, 
NO2
-, NO3













































Gender       
     Female 55 54 54 49 36 31 
     Male 30 29 29 17 24 13 
ICIQ-OAB 
characteristics 








































































NO: Nitric oxide; NO2
-: Nitrite; NO3
-: Nitrate; n: Number of participants included in the analysis; SD: Standard 
Deviation; a Symptom scores were range standardised on a 0 to 1 scale. Urinary concentrations of NO, NO2
-, 
NO3






Figure A2. Associations of nitric oxide (NO), nitrite (NO2
-), nitrate (NO3
-) and the ratio of 
urinary ATP and/or ADP to NO with overactive bladder for male and females. (A) a. 
Correlation between the urinary levels of NO and participants’ total ICIQ-OAB severity 
scores; b. Correlation between the ratio of urinary ATP to NO and participants’ total ICIQ-
OAB severity scores; c. Correlation between the ratio of urinary ADP to NO and participants’ 
total ICIQ-OAB severity scores. (B) a. Correlation between participants’ urinary ATP and ADP; 
b. Correlation between the ratio of the combination of urinary ATP and ADP to NO and 
participants’ total ICIQ-OAB severity scores. 
Urinary concentrations of NO, ATP and ADP were normalized to urinary creatinine (Cr) 
concentration. p: p-value. r: Spearman/Pearson r value. P<0.05 are in bold. All data 
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